Supreme Address

Supreme Court to Address Induced Infringement Claims in Generic ‘Skinny Label’ Drug Marketing Dispute

The U.S. Supreme Court has granted certiorari in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. to resolve whether generic drug makers’ marketing statements can support inducement claims of patent infringement when using skinny labels that omit patented uses. The case tests the boundaries of Hatch-Waxman’s Sect…